June 24th 2024- Dr. Tamar Tadmor- Supplement of Vitamin D for early-stage Chronic Lymphocytic Leukemia Patients is Associated with a Longer Time to first Treatment

CME Congresses .

June 24th 2024- Dr. Tamar Tadmor- Supplement of Vitamin D for early-stage Chronic Lymphocytic Leukemia Patients is Associated with a Longer Time to first Treatment

June 17th 2024- Prof. Saad Usmani- Antigen Escape as a Shared Mechanism of Resistance to BCMA-Directed Therapies in Multiple Myeloma

CME Congresses .

June 17th 2024- Prof. Saad Usmani- Antigen Escape as a Shared Mechanism of Resistance to BCMA-Directed Therapies in Multiple Myeloma

June 11th 2024- Dr. Zachariah DeFilipp- Flares of Acute Graft-Versus-Host Disease: a Mount Sinai Acute GVHD International Consortium Analysis

CME Congresses .

June 11th 2024- Dr. Zachariah DeFilipp- Flares of Acute Graft-Versus-Host Disease: a Mount Sinai Acute GVHD International Consortium Analysis

June 3rd 2024- Prof Saad Usmani- CD8 Effector T Cells Enhance Teclistamab Response in BCMA-Exposed and -Naïve Multiple Myeloma

CME Congresses .

June 3rd 2024- Prof Saad Usmani- CD8 Effector T Cells Enhance Teclistamab Response in BCMA-Exposed and -Naïve Multiple Myeloma

May 24th 2024- Dr. Ruth Namazzi- Hydroxyurea reduces infections in children with sickle cell anemia in Uganda

CME Congresses .

May 24th 2024- Dr. Ruth Namazzi- Hydroxyurea reduces infections in children with sickle cell anemia in Uganda

May 20th 2024- Dr. Lorenz Bastian- Developmental trajectories and cooperating genomic events define molecular subtypes of BCR:ABL1-positive ALL

CME Congresses .

May 20th 2024- Dr. Lorenz Bastian- Developmental trajectories and cooperating genomic events define molecular subtypes of BCR:ABL1-positive ALL

May 14th 2024- Prof. Didier Blaise- Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

CME Congresses .

May 14th 2024- Prof. Didier Blaise- Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

May 7th 2024- Prof. Ibrahim Yakoub-Agha- Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

CME Congresses .

May 7th 2024- Prof. Ibrahim Yakoub-Agha- Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

April 30th 2024- Dr. Fadi Haddad & Prof. Elias Jabbour- Phase 2 Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission

CME Congresses .

April 30th 2024- Dr. Fadi Haddad & Prof. Elias Jabbour- Phase 2 Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission

April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

CME Congresses .

April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations